Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

UK 453,061

Known as: UK453061, UK 453061, UK-453061 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Objective:A 96-week clinical study was planned to estimate the antiviral activity and safety of lersivirine in treatment-naive… Expand
2012
2012
OBJECTIVE A 96-week clinical study was planned to estimate the antiviral activity and safety of lersivirine in treatment-naive… Expand
2012
2012
AIMS To investigate the effect of inhibitors of cytochrome P450 (CYP) 3A4 and glucuronidation (UGT2B7) on the pharmacokinetics of… Expand
Highly Cited
2010
Highly Cited
2010
ABSTRACT The nonnucleoside reverse transcriptase inhibitors (NNRTIs) are key components of highly active antiretroviral therapy… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
2010
2010
Lersivirine [UK-453,061, 5-((3,5-diethyl-1-(2-hydroxyethyl)(3,5-14C2)-1H-pyrazol-4-yl)oxy)benzene-1,3-dicarbonitrile] is a next… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Highly Cited
2009
Highly Cited
2009
We prepared three discreet cohorts of potent non-nucleoside HIV reverse transcriptase inhibitors (NNRTIs) based on the recently… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
2009
2009
Objective:To investigate the effects on viral load and assess dose–response relationships, pharmacokinetics, safety and… Expand
2009
2009
The requirements for safe testing of pharmaceuticals in humans places substantial emphasis on the translation of safety testing… Expand
2008
2008
1. UK-453,061 is a novel second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI). Following intravenous bolus… Expand